These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31733406)

  • 21. [Consequences of the judicialization of health policies: the cost of medicines for mucopolysaccharidosis].
    Diniz D; Medeiros M; Schwartz IV
    Cad Saude Publica; 2012 Mar; 28(3):479-89. PubMed ID: 22415180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. India moves closer to regulating prices of patented drugs.
    Kay M
    BMJ; 2014 Jan; 348():g1244. PubMed ID: 24480395
    [No Abstract]   [Full Text] [Related]  

  • 23. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Price regulation in the pharmaceutical industry: prescription or placebo?
    Abbott TA
    J Health Econ; 1995 Dec; 14(5):551-65. PubMed ID: 10156501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 29. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Price controls: on the one hand ... and on the other.
    Langwell K
    Health Care Financ Rev; 1993; 14(3):5-10. PubMed ID: 10130583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Price regulation, industry structure and innovation: an international comparison of pharmaceutical industries.
    Thomas LG
    Pharmacoeconomics; 1992; 1(Suppl 1):9-12. PubMed ID: 10146925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders].
    de Souza MV; Krug BC; Picon PD; Schwartz IV
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3443-54. PubMed ID: 21120332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parallel imports, price controls, and innovation.
    Reisinger M; Saurí L; Zenger H
    J Health Econ; 2019 Jul; 66():163-179. PubMed ID: 31202122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
    Lauenroth VD; Stargardt T
    Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. California's Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing.
    Gudiksen KL; Brown TT; Whaley CM; King JS
    Health Aff (Millwood); 2018 Sep; 37(9):1503-1508. PubMed ID: 30179546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.